Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.
Many multiple sclerosis (MS) patients treated with interferon-beta (IFNbeta) develop anti-IFNbeta antibodies (BAbs), which can interfere with both in vitro and in vivo bioactivity of the injected cytokine. Objective of this study was to correlate these measures. Among the 256 enrolled patients, 11 (4.3%) showed a significant inhibition of the IFNbeta activity in vitro, but no measurable BAbs. As a whole, in vivo bioactivity was inhibited in 9/11 (82%) of these patients. A minority of IFNbeta treated patients have a non-antibody mediated neutralising activity, which competitively inhibits the bioactivity both in vitro and in vivo.
Gilli
Francesca
F
Centro di Riferimento Regionale Sclerosi Multipla (CReSM) & Neurobiologia Clinica, ASO S. Luigi Gonzaga, Orbassano, Torino, Italy. neurobiologia@sanluigi.piemonte.it
Marnetto
Fabiana
F
Caldano
Marzia
M
Valentino
Paola
P
Granieri
Letizia
L
Di Sapio
Alessia
A
Capobianco
Marco
M
Sala
Arianna
A
Malucchi
Simona
S
Kappos
Ludwig
L
Lindberg
Raija L P
RL
Bertolotto
Antonio
A
D000906:Antibodies / Q000627:therapeutic use*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D019204:GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D047468:Immunoprecipitation; D066298:In Vitro Techniques; D016899:Interferon-beta / Q000276:immunology* / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy; D064547:Myxovirus Resistance Proteins; D009500:Neutralization Tests; D017471:Receptors, Interferon / Q000378:metabolism; D012189:Retrospective Studies
D000906:Antibodies; D064547:Myxovirus Resistance Proteins; D017471:Receptors, Interferon; D016899:Interferon-beta; D019204:GTP-Binding Proteins